Clinical Trial Update: Real-life-persistence to Antifibrotic Treatments

View source ↗

Summary

A completed real-world study from Boehringer Ingelheim examining how patients with idiopathic pulmonary fibrosis persist with antifibrotic therapies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Esbriet (pirfenidone)
• OFEV (Nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Status: COMPLETED